1,2,5-oxadiazoles as inhibitors of indoleamine 2,3-dioxygenase
US-9789094-B2 · Oct 17, 2017 · US
1,2,5-oxadiazoles as inhibitors of indoleamine 2,3-dioxygenase
US10034864B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-10034864-B2 |
| Application number | US-201715442876-A |
| Country | US |
| Kind code | B2 |
| Filing date | Feb 27, 2017 |
| Priority date | Jul 8, 2008 |
| Publication date | Jul 31, 2018 |
| Grant date | Jul 31, 2018 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
The present invention is directed to 1,2,5-oxadiazole derivatives, and compositions of the same, which are inhibitors of indoleamine 2,3-dioxygenase and are useful in the treatment of cancer and other disorders, and to the processes and intermediates for making such 1,2,5-oxadiazole derivatives.
First claim
Opening claim text (preview).
What is claimed is: 1. A method of inhibiting or ameliorating a cancer selected from renal cancer, lung cancer, and head and neck cancer in a patient, comprising administering to said patient a therapeutically effective amount of a compound, which is 4-({2-[(amino sulfonyl)amino]ethyl}amino)-N-(3-bromo-4-fluorophenyl)-N′-hydroxy-1,2,5-oxadiazole-3-carboximidamide, or a pharmaceutically acceptable salt thereof, in combination with an antibody therapeutic. 2. The method of claim 1 , wherein the cancer is renal cancer. 3. The method of claim 2 , wherein the antibody therapeutic is an anti-PD-1 antibody. 4. The method of claim 2 , wherein the antibody therapeutic is an anti-CTLA-4 antibody. 5. The method of claim 1 , wherein the cancer is lung cancer. 6. The method of claim 5 , wherein the antibody therapeutic is an anti-PD-1 antibody. 7. The method of claim 5 , wherein the antibody therapeutic is an anti-CTLA-4 antibody. 8. The method of claim 1 , wherein the cancer is head and neck cancer. 9. The method of claim 8 , wherein the antibody therapeutic is an anti-PD-1 antibody. 10. The method of claim 8 , wherein the antibody therapeutic is an anti-CTLA-4 antibody. 11. A method of inhibiting or ameliorating a cancer selected from renal cancer, lung cancer, and head and neck cancer in a patient, comprising administering to said patient a therapeutically effective amount of a compound, which is 4-({2-[(amino sulfonyl)amino]ethyl}amino)-N-(3-bromo-4-fluorophenyl)-N′-hydroxy-1,2,5-oxadiazole-3-carboximidamide in combination with an antibody therapeutic. 12. The method of claim 11 , wherein the cancer is renal cancer. 13. The method of claim 12 , wherein the antibody therapeutic is an anti-PD-1 antibody. 14. The method of claim 12 , wherein the antibody therapeutic is an anti-CTLA-4 antibody. 15. The method of claim 11 , wherein the cancer is lung cancer. 16. The method of claim 15 , wherein the antibody therapeutic is an anti-PD-1 antibody. 17. The method of claim 15 , wherein the antibody therapeutic is an anti-CTLA-4 antibody. 18. The method of claim 11 , wherein the cancer is head and neck cancer. 19. The method of claim 18 , wherein the antibody therapeutic is an anti-PD-1 antibody. 20. The method of claim 18 , wherein the antibody therapeutic is an anti-CTLA-4 antibody.
Assignees
Inventors
Classifications
Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00 · CPC title
Immunosuppressants, e.g. drugs for graft rejection · CPC title
Immunostimulants · CPC title
Drugs for immunological or allergic disorders · CPC title
specific for leukemia · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US10034864B2 cover?
- The present invention is directed to 1,2,5-oxadiazole derivatives, and compositions of the same, which are inhibitors of indoleamine 2,3-dioxygenase and are useful in the treatment of cancer and other disorders, and to the processes and intermediates for making such 1,2,5-oxadiazole derivatives.
- Who is the assignee on this patent?
- Incyte Corp, Incyte Holdings Corp
- What technology area does this patent fall under?
- Primary CPC classification C07D271/08. Mapped technology areas include Chemistry & Metallurgy.
- When was this patent published?
- Publication date Tue Jul 31 2018 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 9 related publications on this page (citations in our corpus or others sharing the same primary CPC).